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Abstract
Objectives—To evaluate the safety of gadoxetic acid disodium (Gd-EOB-DTPA) magnetic
resonance imaging (MRI) and its efficacy in characterizing liver lesions.
Methods—Lesion characterization and classification using combined (unenhanced and Gd-EOB-
DTPA–enhanced) MRI were compared with those using unenhanced MRI and contrast-enhanced
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spiral computed tomography (CT) using on-site clinical and off-site blinded evaluations for
patients with focal liver lesions.
Results—Gadoxetic acid disodium was well tolerated in this study. For the clinical evaluation,
more lesions were correctly characterized using combined (unenhanced and Gd-EOB-DTPA–
enhanced) MRI than using unenhanced MRI and spiral CT (96% vs 84% and 85%, respectively; P
≤ 0.0008). For the blinded evaluation, more lesions were correctly characterized using combined
MRI compared with using unenhanced MRI (61%–76% vs 48%–65%, respectively; P ≤ 0.0012
for 2/3 readers); when compared with spiral CT, a similar proportion of lesions were correctly
characterized.
Conclusions—Gadoxetic acid disodium–enhanced MRI is of clinical benefit relative to
unenhanced MRI and spiral CT for a radiological diagnosis of liver lesions.
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Improved imaging accuracy in hepatic lesion characterization is crucial for appropriate
patient triage. Dynamic contrast-enhanced magnetic resonance imaging (MRI) has remained
for more than 10 years as the established technique to characterize detected liver lesions1–4;
however, further improvement in lesion detection and characterization would be desirable.
Currently approved liver-specific contrast agents, such as ferumoxides and mangafodipir,5–7
lack dynamic enhancement information,8 and dual contrast-enhanced MRI is cumbersome
and not in widespread use.9,10
Gadoxetic acid disodium (Gd-EOB-DTPA: Primovist [Bayer Schering Pharma AG, Berlin,
Germany], Eovist [Bayer Healthcare Pharmaceuticals, Wayne, NJ], and EOB-Primovist
[Bayer Yakuhin, Osaka, Japan]) is a newly developed liver-specific MRI contrast agent that
was first approved in Europe in 2004 and is also approved in many countries of the Asia-
Pacific region. More recently, in July 2008, Gd-EOB-DTPAwas approved by the Food and
Drug Administration in the United States for intravenous use in T1-weighted (TW1) MRI of
the liver to detect and characterize lesions in adults with known or suspected focal liver
lesions. Gadoxetic acid disodium has extracellular properties similar to conventional Gd-
containing extracellular MRI contrast agents but has the additional property of selective
hepatocyte uptake, with approximately 50% of the injected dose taken up via the organic
anion transporter protein (OATP-1) followed by biliary excretion.11–13 Gadoxetic acid
disodium also has higher relaxivity rates compared with Gd-DTPA (6.9 L mmol−1 s−1 in
plasma at 1.5 T vs 4.1 L mmol−1 s−1 in plasma at 1.5 T).14 Phase 1 to 3 trials showed good
tolerance15 and improvement in lesion characterization16–18 and detection.19,20
Here, we present the findings of a phase 3 trial that, in addition to safety evaluations, was
designed to assess whether combined unenhanced and Gd-EOB-DTPA–enhanced MRI
improved liver lesion characterization and classification when compared primarily with




This open-label, phase 3 study was performed at 18 institutions in the United States. It was
an intraindividual comparison of the diagnostic performance of combined unenhanced and
Gd-EOB-DTPA–enhanced MRI and the unenhanced MRI or spiral CT to determine liver
lesion characterization (lesion-specific diagnosis) and classification (benign/malignant). The
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trial protocol was approved by a central ethics committee and 18 local institutional review
boards. All participating patients gave informed written consent.
Patients and Liver Lesions
Patients 18 years and older with suspected or known liver lesions who had been referred to
have routine CT and MRI were eligible to be included in the trial. A total of 240 patients
enrolled in the trial.
Patients were excluded if they could be placed into one of the following categories:
underwent liver surgery before MRI, pregnant or breast-feeding mother, previously received
Gd-EOB-DTPA or other study drugs within 30 days before MRI, received Gd-DTPA within
24 hours or other liver-specific contrast agent within 2 weeks before MRI, clinically
unstable, scheduled for biopsy or surgery within 72 hours of MRI, history of anaphylactoid
reactions to medications or contrast media, lack of appropriate standard of reference (SOR)
examination, or not adhering to specified time parameters.
Standard of Reference
All lesions or groups of lesions in the study were verified by a predefined, lesion-specific,
and ethically justifiable SOR, generally within 3 months of MRI. The following lesion-
specific SORs were considered valid if performed within the following timeframes:
malignancies, biopsy within 3 months; focal liver fibrosis or fat, biopsy within 12 months;
regenerative nodules, biopsy within 4 weeks; adenoma, biopsy within 6 months; focal
nodular hyperplasia, biopsy or conventional dynamic contrast-enhanced MRI within 12
months; hemangiomas, conventional dynamic contrast-enhanced MRI or tagged cell
scintigraphy (for lesions > 2 cm) within 12 months; liver cysts, sonography within 12
months; hydatid cysts, sonography and serology within 2 weeks; and abscess, aspiration and
culture within 2 weeks.
Magnetic Resonance Contrast Agent
Gadoxetic acid disodium is a liver-specific MR contrast agent; its chemical profile,
pharmacokinetic properties (hepatocellular uptake via OATP-1 of approximately 50% of the
dose), relaxivity rates (6.9 L mmo−1 s−1 in plasma at 1.5 T), osmolality, viscosity, and
physiological routes of excretion (balanced renal and biliary) have been described
previously.11–13,15
The patients received a 25 μmol/kg body weight dose of a 0.25-mol/L solution of Gd-EOB-
DTPA (volume range, 4.0–12.0 mL), which was bolus injected at 2 mL/s through a cubital
intravenous line and then flushed with 30 mL of 0.9% saline.
Safety Evaluation
The patients were observed and evaluated for adverse events (AEs) for 72 hours after the
administration of Gd-EOB-DTPA. All subjective and objective AEs were recorded. Vital
signs, 12-lead electrocardiograms, and clinical laboratory tests (hematological, coagulation,
and clinical chemistry tests and urinalysis) were obtained at multiple time points in all the
patients.
Magnetic Resonance Imaging
Magnetic resonance imaging was performed using the 1.5-T MR Systems with phased array
surface coils. Each patient first underwent the following precontrast sequences: T2W fast
spin echo (FSE)/turbo spin echo/single-shot FSE/half-Fourier acquisition single-shot turbo
spin-echo sequence (repetition time, ≥2000 milliseconds; echo time, 90–120 milliseconds;
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number of excitations, 1–4; matrix, 192–256 × 256; slice thickness, 5–8 mm; gap, 0–2 mm;
breath hold and fat suppression, optional) and T1W 2-dimensional gradient-recalled echo
(GRE) fast low-angle shot (FLASH) sequence with and without chemically selective fat
suppression (repetition time, 100–200 milliseconds; echo time, ≤8 milliseconds; matrix,
128–256 × 256; slice thickness, 5–8 mm; gap, 0–2 mm). After completion of the intravenous
injection of Gd-EOB-DTPA, breath-hold 2-dimensional GRE/FLASH T1 sequences in the
arterial (10–20 seconds), portovenous (50–60 seconds), and equilibrium phases (100–120
seconds) were acquired. The T2W and T1W sequences were repeated 20 minutes after Gd-
EOB-DTPA injection.
Computed Tomography
Biphasic spiral CTwas performed on predominantly single-detector scanners (100 to 150
kV; 180–300 mAs; pitch, 1 to 2; and slice thickness and reconstruction interval, 5 to 7 mm).
Using a power injector, 3 to 5 mL/s (100–200 mL) of iodinated, nonionic contrast material
was administered intravenously. Hepatic arterial and portal venous phase imagings were
performed after a delay of 25 to 35 seconds and 45 to 70 seconds, respectively, after the start
of contrast injection.
Image Evaluation
The MR and CT images were reviewed either unblindedly on site by one experienced
clinical investigator per study site to mimic routine clinical practice or blindedly off site by 3
experienced abdominal image radiologists (readers 1, 2, and 3) who were not involved in the
unblinded image review (blinded off-site evaluations were performed by a central core
laboratory).
Lesion Identification
For correct lesion identification and to eliminate confusion in cases with multiple lesions,
each SOR-proven lesion was marked on both the MR and CT images by the clinical
investigator and assigned a unique number, which was used throughout the study on all
imaging sequences.
Image Evaluation in the Clinical Study
For all MR images, the clinical investigator first assessed the T1W and T2W unenhanced
images followed by the combined MR sequences (unenhanced images, T1W dynamic
enhanced images, T1W delayed hepatocyte-specific images, and postcontrast T2W images).
Each clinical investigator separately assessed the images from the dual-phase spiral CT.
They recorded their evaluations with respect to characterization, classification, and
confidence during the prospective reading in a detailed modality-specific record.
Image Evaluation in the Blinded Off-Site Review
The off-site evaluation was performed in 3 sessions separated by two 3-week intervals to
minimize recall and memory bias. The readers were blinded to the patient-related
information, the imaging technique, and the contrast information. During the first session,
the readers evaluated all the unenhanced images (T1W and T2W) separately from the
enhanced images (T1W dynamic, T1W delayed hepatocyte-specific images, and
postcontrast T2W images) in a random patient order. In the second session, the combined
MR images (unenhanced and dynamic and delayed) were evaluated. The dual-phase spiral
CT images were reviewed during the third session. Each reader assessed every image for all
the patients.
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In both the on-site clinical and off-site blinded evaluations, the primary end point was the
performance of combined MRI (unenhanced and Gd-EOB-DTPA–enhanced) compared with
unenhanced MRI in characterizing focal lesions (as measured by the proportion of detected
lesions with correct characterization). This intended to reflect real-life clinical practice
because both unenhanced and enhanced MR images are used together for evaluation of
lesions in clinical practice. Correct lesion characterization was achieved when radiological
interpretation agreed with the SOR diagnosis.
Secondary end points included the comparison of the performance of combined MRI versus
spiral CT in characterizing focal liver lesions in both the on-site clinical and off-site blinded
evaluations and the comparison of the characterization performance of Gd-EOB-DTPA–
enhanced MRI (dynamic and delayed hepatocyte-specific images [20 minutes after
administration]) versus unenhanced MRI only in the blinded evaluation.
The clinical and blinded readers graded the confidence of characterization for each lesion on
a 5-point scale for unenhanced MRI, combined MRI, and spiral CT data. A score of 1
indicated low or doubtful confidence that lesion morphology and enhancement were
characteristic of a specific lesion type, whereas a score of 5 indicated highest confidence that
the spiral CTand MRI features were characteristic of specific lesion types.
Analysis of discordant lesions, defined as those correctly characterized by one modality but
incorrectly characterized by another modality, was performed in the clinical and blinded
reviews.
Both the unblinded clinical on-site and blinded off-site readers classified each representative
lesion as malignant, benign, or not assessable during the review of images from the
unenhanced and combined MRI and CT. The readers also scored the confidence of
classification of each individual lesion based on standard radiological signs on a 5-point
scale, where 1 indicated low or doubtful confidence and 5 indicated complete confidence
that the radiological features ascribed to the lesion were representative of each lesion
category.
Accuracy, sensitivity, and specificity of lesion classification were calculated separately for
spiral CT and for enhanced, unenhanced, and combined MRI compared with the SOR.
Because the SOR was defined as the criterion standard, the assessment “not assessable” was
not accepted as a result of the reference standard.
Statistical Analysis
The primary objectives were to calculate the proportion of detected lesions with correct
characterization (lesion diagnosis) on combined MRI or enhanced MRI compared with that
on unenhanced MRI and to show superiority. Performance in lesion characterization was
evaluated on a per-lesion basis for each patient and for all the patients. Because some
patients may have had multiple lesions detected and verified by the SOR, an adjustment of
the 2-tailed McNemar test of paired proportions, proposed by Eliasziw and Donner21 to take
into account clustering, was used for this hypothesis test at a 5% significance level.
Results
Of the 240 patients enrolled in the trial, 5 did not receive intravenous Gd-EOB-DTPA. A
total of 197 patients had a valid lesion-specific SOR; however, 20 had protocol deviations
and were excluded from the efficacy analysis. Thus, 177 patients were eligible to be
included in the efficacy analysis. All 235 patients who received Gd-EOB-DTPA were
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included in the safety analysis. There were 124 men (53%) and 111 women (47%) with the
mean age of 54.2 years (range, 22–81 years).
Safety of Gd-EOB-DTPA
The contrast medium was well tolerated by patients. Fifty-two AEs occurred in 39 (16.6%)
of the 235 patients after administration of a contrast injection, of which 14 AEs in 12
patients (5.1%) were considered by the investigator to be possibly or probably drug related.
None were considered definitely related to the study drug by the investigator. Adverse
events considered possibly or probably related to the study drug were taste perversion (4
patients), headache (2 patients), vasodilatation (1 patient), nausea (1 patient), bundle branch
block (1 patient), rash (1 patient), maculopapular rash (1 patient), dizziness (1 patient),
diarrhea (1 patient), and dry mouth (1 patient). No patients discontinued the study. There
were no clinically relevant changes in the clinical, electrocardiogram, or laboratory
parameters in any patients.
Efficacy
A total of 269 lesions with an SOR in 177 patients were included for efficacy analysis, of
which 92 lesions were malignant and 177 were benign. The primary malignancies consisted
of 38 patients with hepatocellular carcinoma, 4 patients with cholangiocarcinomas, and 2
patients with focal lymphomas. Most liver metastases originated from colorectal, gastric, or
pancreatic adenocarcinomas (44/48 patients).
The benign lesions consisted of 67 hemangiomas, 37 focal nodular hyperplasias, 54 simple
cysts, 10 focal fat, 4 regenerative nodules, 2 adenomas, 1 abscess, and 1 bile duct adenoma,
and one patient had only normal liver tissue and no lesion.
On-site Evaluation (Clinical Study)
Primary Evaluation—In 177 patients, the proportion of correctly characterized lesions
was significantly higher using combined MRI (96%) compared with either unenhanced MRI
(84%; P = 0.0002) or spiral CT (85%; P = 0.0008; Table 1).
The number of patients evaluated for the primary end point was different to the number of
patients evaluated for the comparison of MRI and spiral CT because in some patients, spiral
CT was not performed or was not performed within 6 weeks of MRI.
Secondary Evaluation—Of the discordant lesions, 11.5% (31/269) were correctly
characterized using combined MRI but incorrectly characterized using unenhanced MRI,
whereas only 0.4% (1/269) were correctly characterized using unenhanced MRI alone. In
comparison, 11.9% (31/261) of the lesions were correctly characterized by combined MRI
but incorrectly characterized by spiral CT; a total of 1.1% (3/261) of the lesions were
correctly characterized by spiral CT alone.
When assessing the confidence of lesion characterization, a greater proportion of lesions
were assigned with high confidence (4 or 5) with combined MRI compared with that with
spiral CT or unenhanced MRI (92% [236/269 lesions] versus 62% [140/269 lesions] or 79%
[174/221 lesions], respectively; Table 2).
The proportion of lesions with a correct classification (benign or malignant) was also highest
for combined MRI (98% [264/269 lesions]), relative to unenhanced MRI (92% [247/269
lesions]) or spiral CT (88% [230/261 lesions]). The highest confidence of classification
scores (4 or 5) were reported using combined MRI (94% [246/262]) compared with
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unenhanced MRI (66% [155/235]) and spiral CT (81% [185/227]). Sensitivity, specificity,
and accuracy were all highest for combined MRI (Table 3).
Off-site Blinded Evaluation
Primary Evaluation—All 3 blinded readers correctly characterized more lesions using
combined MRI relative to unenhanced MRI. The proportion of correctly characterized
lesions increased by 1%, 11%, and 19% for readers 1, 2, and 3, respectively, with significant
improvement (P ≤ 0.0012) for 2 of 3 readers (Table 4; Figs. 1–3).
Secondary Evaluation—All the readers correctly characterized a greater proportion of
the lesions using enhanced MR sequences compared with unenhanced MR sequences
(significant for 2 of the 3 readers; reader 1, P = 0.859; reader 2, P = 0.0001; reader 3, P =
0.0002; Table 5, enhanced sequences vs unenhanced sequences). Similarly, all the readers
correctly characterized a greater proportion of the lesions using combined MR images
compared with dual-phase spiral CT (not significantly different for any of the readers; Table
5, combined MRI vs spiral CT).
Of the discordant lesions, all the readers correctly characterized more lesions using
combined or enhanced MRI (Tables 6) relative to unenhanced MRI or spiral CT.
Conversely, fewer lesions were correctly characterized using unenhanced MRI or spiral CT
than on enhanced or combined MRI. Confidence of characterization was highest for all
readers on combined MR sequences (Table 7).
In analysis of lesion classification as benign or malignant, most readers (2 of 3) correctly
classified more lesions using combined MRI relative to unenhanced MRI (77% vs 78%,
89% vs 87%, and 85% vs 79% for readers 1, 2, and 3, respectively), and all the readers
correctly classified more lesions using combined MRI relative to spiral CT (65%, 82%, and
77% for readers 1, 2, and 3, respectively; Table 8), with highest confidence using combined
MRI (75%–98%, 69%–78%, and 64%–89% for combined MRI, unenhanced MRI, and
spiral CT, respectively; Table 9).
For the blinded analysis, when comparing combined MRI with unenhanced MRI, sensitivity
and accuracy for lesion classification increased slightly for 2 of 3 readers (sensitivity: 96%
vs 93%, 97% vs 94%, and 80% vs 87%; accuracy: 79% vs 79%, 89% vs 88%, and 83% vs
80%, for readers 1, 2, and 3, respectively); specificity increased for 1 of the 3 readers and
was unchanged for the 2 other readers (67% vs 67%, 83% vs 83%, and 83% vs 80% for
readers 1, 2, and 3, respectively). The accuracy for lesion classification was highest in
combined MRI compared with spiral CT for all readers (Table 10).
Discussion
Most of the previously published studies that have determined the accuracy of MRI have
focused on lesion detection as a primary end point with variable rigorousness of lesion
verification.22–24 However, for maximal clinical utility, improved detection, classification,
and characterization of lesions are necessary for widespread use of any liver agent because
clinical therapy decisions rely on the knowledge of malignancy and the diagnosis of a
specific lesion type. Our study was specifically designed to assess the diagnostic
performance for the classification and characterization of focal liver lesions using combined
MRI using the liver-specific contrast agent, Gd-EOB-DTPA.
With Gd-EOB-DTPA–enhanced MRI, both dynamic enhancement information (such as
conventional Gd-DTPA–enhanced MRI)25 and delayed (20 minutes) T1 hepatocyte-specific
enhancement (such as manganese dipyridoxal diphosphate)7 are obtained. Superior lesion
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detection was shown in recent multi-center trials using Gd-EOB-DTPA–enhanced MRI
when compared with unenhanced MRI.19,20 Sensitivity was higher, and fewer false-positive
lesions resulted with Gd-EOB-DTPA–enhanced MRI compared with spiral CT, especially
when lesions less than 1 cm were considered.18 However, large multicenter studies are
needed to evaluate the value of Gd-EOB-DTPA–enhanced MRI for characterization of focal
liver lesions.
Here, we report a phase 3, multicenter trial conducted in the United States, where a 1.5-T
MRI was used to determine whether Gd-EOB-DTPA–enhanced MRI improved hepatic
lesion characterization and classification both clinically and in independent, blinded reader
evaluation relative to unenhanced scans and, secondarily, to standard dual-phase spiral CT.
A wide variety of rigorously proven benign and malignant lesions were imaged.
In both the clinical and blinded evaluations, in comparison with unenhanced MR images,
combined unenhanced and Gd-EOB-DTPA–enhanced MRI significantly improved focal
hepatic lesion characterization. In the blinded reading, a secondary comparison of enhanced
and unenhanced sequences showed that all the 3 readers improved lesion characterization
performance when enhanced sequences were used. Furthermore, in both the clinical and
blinded evaluations, the combined MRI enabled the best lesion classification (benign or
malignant) and improved confidence of classification compared with the unenhanced MRI
and the spiral CT in both evaluations.
In these analyses, the combined MR sequences allowed improved characterization compared
with the spiral CT, as shown by the primary evaluation and the discordant lesion evaluation.
The difference was larger in the clinical study because of its unblinded nature, which either
reflects true clinical practice or may indicate bias where additional information often
influences radiological interpretations.26–28
In addition to the objective parameters, which included the proportion of correctly
characterized lesions or any sensitivity and specificity calculation, the evaluation of the
confidence in characterization is an important supportive parameter for the performance of
an imaging method because triage to further radiological investigations, biopsy, or therapy is
influenced by the degree of radiological confidence. In both evaluations, combined MRI had
the highest confidence scores with respect to lesion characterization, which is clinically
important because the radiologist's confidence impacts further patient management.
Limitations regarding the study design have been considered. Not all benign lesions (15.6%
[31/199]) had histological proof as SOR because biopsies of benign liver lesions, such as
hemangiomas or focal nodular hyperplasia, were not the standard of care and therefore not
ethically justifiable. In addition, we did not subanalyze the utility of each individual
enhancement phase and thus did not address the relative value of the dynamic and
hepatocyte-specific phases.
In summary, Gd-EOB-DTPA–enhanced MRI is safe and significantly improves the ability
to characterize and classify a variety of focal hepatic lesions relative to unenhanced MRI
and dual-phase spiral CT.
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Focal nodular hyperplasia in a female patient aged 47 years. Using dual-phase helical CT, a
segment 2 lesion enhances avidly in the arterial phase (A) and becomes isodense to the liver
in the portal venous phase (B). No discrete scar was present on this or several other similar
lesions (not shown), and the lesions were incorrectly interpreted as hypervascular metastases
on blinded reading. Using unenhanced MRI, the lesion was of intermediate hyperintensity
on the T2W images with hyperintense central scar (C) and mild hyperintensity on the T1W
images (D). Using dynamic Gd-EOB-DTPA–enhanced sequences, the lesions also enhanced
avidly in the late arterial phase (E) with enhancement of the central scar in the portal venous
phases (F). At 20 minutes after injection, the hepatocellular lesion retains contrast (G). The
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other lesions also showed similar characteristics and were correctly interpreted as focal
nodular hyperplasia on blinded reading of combined images.
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Hemangiomas in a female patient aged 30 years. Using dual-phase helical CT, nodular
peripheral enhancement is present in a segment 4 lesion in the arterial phase (A) with
progressive enhancement in the portal venous phase (B). Other similar lesions (not shown)
were present with similar features, and the lesions were interpreted as hemangiomas on
blinded reading. Using unenhanced MRI, the lesion was uniformly and markedly
hyperintense on T2W images (C) and hypointense on T1W images (D) and interpreted as a
simple cyst. Using dynamic Gd-EOB-DTPA–enhanced sequences, the lesions also showed
characteristic progressive nodular peripheral enhancement in the late arterial (E) and portal
venous phases (F). At 20 minutes after injection, the lesion signal has decreased in
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comparison with the background liver (G). Based on combined images, the lesions were
interpreted as hemangiomas.
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Hepatocellular carcinoma in a male patient aged 75 years with proven histopathology. Using
dual-phase helical CT, a segment 7 mass markedly enhances compared with the liver (A)
and then rapidly becomes isointense with capsular enhancement in the portal venous phase
(B). The mass was interpreted as a hepatocellular carcinoma on blinded reading. On
unenhanced MRI, the mass was of intermediate hyperintensity on the T2W images (C) and
hypointense on the T1W images (D) and interpreted as a hemangioma. Using dynamic Gd-
EOB-DTPA–enhanced sequences, the mass enhanced avidly relative to liver late arterial
phase (E) and then unenhanced with delayed capsular enhancement in the late portal venous
phase (F). At 20 minutes after injection, the lesion signal was hypointense in comparison to
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the background liver (G). Using combined images, the lesion was interpreted as a
hepatocellular carcinoma. Overall confidence of characterization was stronger for combined
images relative to the CT images alone.
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TABLE 1
Clinical Evaluation: Proportion of Correctly Characterized Lesions
Correctly Characterized Lesions, n (%) 95% Confidence Interval P*
Combined MRI†
(n = 269 lesions)
257 (96) — —
Unenhanced MRI
(n = 269 lesions)
227 (84) 0.055–0.167 0.0002
Spiral CT
(n = 261 lesions)
222 (85) 0.047–0.167 0.0008
*
P value versus combined MRI.
†
Combination of unenhanced and enhanced MR sequences.
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TABLE 2
Clinical Evaluation: Confidence of Lesion Characterization
Imagining Technique Percentage of Lesions Assigned 4 or 5, n (%)
Combined MRI† (n = 269 lesions) 236 (92)
Unenhanced MRI (n = 269 lesions) 140 (62)
Spiral CT (n = 221 lesions) 174 (79)
Confidence of lesion characterization was defined using a 5-point scale: 1 indicates low or doubtful confidence, whereas 5 indicates high or
complete/almost complete confidence. Combination of unenhanced and enhanced MR sequences.
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TABLE 3
Clinical Evaluation: Test Parameters for Lesion Classification (Benign/Malignant)
Comparing Combined MRI With Unenhanced MR and Spiral CT
Combined MRI (n = 269 Lesions) Unenhanced MRI (n = 269 Lesions) Spiral CT (n = 261 Lesions)
TP, n (%) 93 (35) 85 (32) 77 (30)
TN, n (%) 171 (64) 162 (60) 153 (59)
FP, n (%) 4 (1) 13 (5) 17 (7)
FN, n (%) 1 (<0) 9 (3) 14 (5)
Sensitivity, % 99.4 90 89.3
Specificity, % 96.0 91.8 88.9
Accuracy, % 97.5 90.9 89.1
Includes only lesions verified by SOR.
FN indicates false negatives (benign, no lesion, or not assessable in the imaging procedure but malignant in SOR); FP, false positives (malignant or
not assessable in the imaging procedure but benign or no lesion in the SOR); TN, true negatives (benign or no lesion in the imaging procedure and
in SOR); TP, true positives (malignant in the imaging procedure and in the SOR)
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TABLE 4
Blinded Evaluation: Primary Analysis of the Proportion of Correctly Characterized
Lesions Using Combined MR Sequences Versus Unenhanced Sequences
Reader Combined MRI, (n = 269 Lesions), n (%) Unenhanced MRI, (n = 269 Lesions), n (%) P
1 163 (61) 161 (60) 0.859
2 204 (76) 174 (65) 0.0012
3 180 (67) 129 (48) ≤0.0001
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TABLE 5
Blinded Evaluation: Secondary Analysis of the Proportion of Correctly Characterized
Lesions
Reader Enhanced MRI (n = 269 Lesions), n (%) Unenhanced MRI (n = 269 Lesions), n (%) P
1 168 (62) 161 (60) 0.859
2 210 (78) 174 (65) 0.0001
3 175 (66) 129 (48) 0.0002
Combined MRI, n (%) Spiral CT, n (%) P
1 (n = 254 lesions) 157 (62) 146 (57) 0.4361
2 (n = 250 lesions) 193 (77) 189 (76) 0.6329
3 (n = 250 lesions) 165 (66) 161 (64) 0.6342
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TABLE 6
Blinded Evaluation: Proportion of the Discordant Lesions
Reader
Characterized Correctly Using Combined MRI but
Incorrect Using Unenhanced MRI (n = 269 lesions), n
(%)
Characterized Correctly Using Unenhanced MRI but
Incorrect Using Combined MRI (n = 269 lesions), n (%)
1 34 (12.6) 32 (12.0)
2 46 (17.1) 16 (6.0)
3 66 (24.5) 15 (6.0)
Characterized Correctly Using Enhanced MRI but
Incorrectly Using Unenhanced MRI (n = 269 lesions), n
(%)
Characterized Correctly Using Unenhanced MRI but
Incorrectly Using Enhanced MRI (n = 269 lesion), n
(%)
1 37 (13.8) 30 (11)
2 46 (17.1) 10 (4)
3 61 (22.7) 15 (6)
Characterized Correctly Using Combined MRI but
Incorrectly Using Spiral CT, n (%)
Characterized Correctly Using Spiral CT but
Incorrectly Using Combined MRI, n (%)
1 (n = 254 lesions) 48 (18.9) 37 (15)
2 (n = 250 lesions) 29 (11.6) 25 (10)
3 (n = 250 lesions) 32 (12.8) 28 (11)
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TABLE 7
Confidence of Characterization in the Blinded Evaluation: Proportion of Lesions
Assigned a Score of 4 or 5
Reader Combined MRI, n (%) Unenhanced MRI, n (%) Spiral CT, n (%)
1 158/163 (97) 118/160 (74) 127/146 (87)
2 159/204 (78) 101/173 (59) 119/188 (63)
3 133/180 (74) 92/129 (71) 107/160 (67)
Confidence of lesion characterization was defined using a 5-point scale: 1 indicates low or doubtful confidence, whereas 5 indicates high or
complete/almost complete confidence.
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TABLE 8
Blinded Evaluation: Proportion of Correctly Classified SOR-Verified Lesions
Reader
Enhanced MRI (n = 269), n
(%)
Combined MRI (n = 269), n
(%)
Unenhanced MRI (n = 269), n
(%) Spiral CT (n = 261), n (%)
1 207 (77) 208 (77) 210 (78) 175 (65)
2 241 (90) 239 (89) 234 (87) 221 (82)
3 226 (84) 228 (85) 212 (79) 206 (77)













Raman et al. Page 25
TABLE 9
Confidence of Classification in the Blinded Evaluation: Proportion of Lesions Assigned a
Score of 4 or 5
Reader Combined MRI n (%) Unenhanced MRI n (%) Spiral CT n (%)
1 204/208 (98) 158/208 (76) 156/175 (89)
2 184/239 (77) 152/222 (69) 140/219 (64)
3 167/223 (75) 156/200 (78) 137/203 (68)
Confidence of lesion characterization was defined using a 5-point scale: 1 indicates low or doubtful confidence, whereas 5 indicates high or
complete/almost complete confidence.
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TABLE 10
Sensitivity, Specificity, and Accuracy for Lesion Classification
Enhanced MRI (n = 269),
Reader 1/2/3, %
Combined MRI (n = 269),
Reader 1/2/3, %
Unenhanced MRI (n = 269),
Reader 1/2/3, %
Spiral CT (n = 250),
Reader 1/2/3, %
Blinded evaluation: raw data for calculating test parameters*
TP 34/34/32 33/33/29 33/33/30 33/29/29
TN 43/56/52 44/55/56 45/54/49 36/60/54
FP 22/9/13 21/10/9 20/11/16 29/6/11
FN 1/1/3 1/1/6 2/2/4 2/6/7
Test parameter percentages for lesion classification (benign/malignant) comparing unenhanced MRI with combined MRI, enhanced MRI, or
spiral CT in the blinded evaluation
Blinded study
 Sensitivity 97/98/90 96/97/80 93/94/87 94/83/82
 Specificity 62/85/76 67/83/84 67/83/74 55/88/80
 Accuracy 78/91/82 79/89/83 79/88/80 72/86/81
*
Includes only lesions verified by SOR.
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